Month: March 2026

Rehovot, Israel, March 20, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a provider of edge artificial intelligence (“AI”) video and data processing solutions for defense and autonomous platforms, today announced a development milestone in its collaboration with Quantum Gyro Ltd. (“Quantum Gyro”), a company developing next-generation quantum-based gyroscope technology. Quantum Gyro has entered into an exclusive license agreement with Quantum X Labs Ltd., its parent company, covering certain quantum gyroscope technology for navigation and global positioning system (“GPS”) replacement applications. Quantum X Labs Ltd. is also the assignee of U.S. Provisional Patent Application No. 64/000,184, filed on March 9, 2026, relating to an advanced nuclear magnetic resonance (“NMR”) gyroscope...

Financing strengthens balance sheet and supports advancement of key development initiatives NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) — Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the Company issued an aggregate of approximately 21,071,667 shares of its common stock at a purchase price of approximately $0.055 per share. Investors also received warrants to purchase up to 19,750,001 additional shares of common stock at an exercise price of $0.12 per share. The warrants have a term of five years from the date of issuance. The securities were offered and sold in...

Tel Aviv, Israel, March 20, 2026 (GLOBE NEWSWIRE) — Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, today announced that its fully-owned subsidiary, Quantum X Labs Ltd. (“Quantum X Labs”), has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for a novel nuclear magnetic resonance (NMR) gyroscope hardware architecture designed to deliver ultra-high precision rotational sensing at significantly lower cost than existing solutions. The technology is based on nuclear magnetic resonance sensing, in which rotation is measured through shifts in the Larmor frequency of nuclear magnetic moments as they progress around an applied magnetic field. By precisely detecting these frequency changes, the system can measure angular rotation with exceptional stability...

Company advances California pilot initiative and expands pipeline of waste-to-energy opportunities IRVINE, CA, March 20, 2026 (GLOBE NEWSWIRE) — Clean Energy Technologies, Inc. (NASDAQ: CETY) (“CETY” or the “Company”), a clean energy company focused on converting waste into renewable energy, announced its participation in the Bioenergy Association of California (BAC) annual meeting held March 17 in Sacramento, where the Company engaged in active project discussions on advancing a California pilot waste-to-clean energy initiative. CETY’s participation as an active BAC member comes at a time of accelerating demand for technologies that convert organic waste into renewable electricity, pipeline biogas, low-carbon fuels, and renewable hydrogen. CETY is currently evaluating multiple project pathways discussed at the meeting, with several...

New York, NY, March 20, 2026 (GLOBE NEWSWIRE) — Muzero Acquisition Corp (Nasdaq: MUZEU) (the “Company”) announced today that, commencing March 23, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Stock Market under the symbols “MUZE” and “MUZEW,” respectively. Those units not separated will continue to trade on the Nasdaq Stock Market under the symbol “MUZEU.” This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these...

ATLANTA, March 20, 2026 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced it will host a conference call at 10:00 AM Eastern Time on Tuesday, March 24, 2026. A webcast of the call may be accessed at https://www.webcaster5.com/Webcast/Page/2243/53791 or in the investor section of the Company’s website at https://ir.perma-fix.com/conference-calls. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers, and by entering access code: 568987. The conference call will be led by Mark J. Duff, Chief Executive Officer, Dr. Louis F. Centofanti, Executive Vice President of Strategic Initiatives, and Ben Naccarato, Executive Vice President and Chief Financial Officer of Perma-Fix Environmental. A...

ORLANDO, Fla., March 20, 2026 (GLOBE NEWSWIRE) — PureCycle Technologies, Inc. (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, announced that PureCycle CEO Dustin Olson will join Gerry Sweeney from ROTH Capital Partners for a fireside chat as part of the 38th Annual ROTH Conference. Olson’s discussion will take place on Monday, March 23, 2026 at 12:00 p.m. EDT and streamed live online. Olson will be sharing information regarding the Company’s global expansion plans and additional updates on PureCycle. The Annual ROTH Conference is one of the largest in the nation for small-cap companies. ROTH combines company presentations, Q&A sessions and management 1-on-1 meetings. The ROTH research team identifies distinguished presenting companies across broad sectors, including consumer, energy, healthcare, industrial...

A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the clinical foundation for Nodify CDT® tests as a critical decision-support tool in the early detection of lung cancer, addressing a significant unmet need in the management of the millions of lung nodules detected annually in the United States.  The study, published in Future Oncology, February 2026, titled Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30mm pulmonary nodules: a retrospective...